HORMONE AND METABOLIC RESEARCH激素与代谢研究
HORMONE AND METABOLIC RESEARCH(英文缩写 HORM METAB RES),ISSN 0018-5043,eISSN 1439-4286,中文译名:激素与代谢研究 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.788 | Q4 |
| 2022 | 2.200 | Q4 |
| 2023 | 2.000 | Q3 |
| 2024 | 1.800 | Q4 |
| 2025 | 2.300 | Q3 |
HORMONE AND METABOLIC RESEARCH 最新收录文献
-
1. Association of progesterone and prolactin with hepatic steatosis in premenopausal women: A prospective cross-sectional study.
PMID:期刊:日期:2026-09-11This study aimed to investigate the association between hepatic steatosis and serum levels of reproductive hormones in premenopausal women, with particular focus on progesterone and prolactin. A total of 87 premenopausal women aged 18-45 years were included in this prospective study. Participants were classified by ultrasonographic steatosis status and grade. Blood samples obtained on day 3 of the menstrual cycle were used to measure follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone, and prolactin levels. Women with overt metabolic and endocrine disorders were excluded. Multivariable logistic regression and receiver operating characteristic analyses were performed. Hepatic steatosis was present in 53 participants (60.9%), whereas 34 participants had no steatosis. Progesterone and prolactin levels were significantly lower in participants with hepatic steatosis than in those without steatosis (0.6 vs. 1.1 ng/mL and 7.9 vs. 11.0 ng/mL, respectively; both <0.001). In multivariable analysis, older age (odds ratio: 1.32, 95% confidence interval: 1.12-1.56; =0.001), higher body mass index (odds ratio: 1.57, 95% confidence interval: 1.19-2.08; =0.002), lower progesterone levels (odds ratio: 0.75, 95% confidence interval: 0.58-0.98; =0.037), and lower prolactin levels (odds ratio: 0.51, 95% confidence interval: 0.34-0.79; =0.002) were independently associated with hepatic steatosis. Estradiol, follicle-stimulating hormone, and luteinizing hormone were not associated with steatosis. Receiver operating characteristic analysis showed a discriminative value for progesterone (area under the curve: 0.751) and prolactin (area under the curve: 0.790). Lower serum progesterone and prolactin levels were associated with hepatic steatosis after adjustment for age and body mass index. These findings support a possible relationship between reproductive hormonal milieu and hepatic steatosis in a selected premenopausal population, while the progesterone finding should be interpreted in the context of early follicular-phase measurement.
-
2. Glucocorticoid Receptor Expression in Whole Blood Cells of Professional Water Polo Athletes during the Competitive Season: A Pilot Study.
PMID:期刊:日期:2026-09-11Regular physical exercise plays a role in modulating the hypothalamic-pituitary-adrenal axis in sedentary individuals, but its effects on athletes remain unclear. As athletes depend on inflammation and micronutrient metabolism to improve, glucocorticoids, which interfere with both, may have an impact on their performances. The objective was to describe the characteristics of the HPA axis in athletes during their training season, as well as determine how high-performance training affects this axis. The inclusion criterion for this prospective observational study was participation as a water polo professional athlete since 2017 and the exclusion criteria were the presence of any chronic disease or the use of any kind of drug that affects the HPA axis during the last 6 months or until the end of the study. Nineteen professional water polo athletes were selected for the analysis of glucocorticoid receptor (isoforms α and β) expression and of glucocorticoid receptor polymorphisms (Bcl-I and A3669G). These analyses were carried out at the beginning of the season (T0), when the athletes were less physically prepared, and again at mid-season (T1) during the peak of physical preparation. The results revealed a good adaptive response in athletes during the progressive stress of the season, characterized by lower expression levels of glucocorticoid receptor alpha and glucocorticoid receptor beta and a lower glucocorticoid receptor alpha/glucocorticoid receptor beta ratio, irrespective of the presence of protective polymorphisms. This adaptation decreases sensitivity to the glucocorticoid receptor, reducing hyper-response to stress, and potentially representing a protective mechanism in athletes. This study explores a plausible theory that relates physical fatigue with the HPA axis and its adaptations.
-
3. Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.
PMID:期刊:日期:2026-09-01The global rise in aging populations has been accompanied by increasing rates of obesity and type 2 diabetes, both of which pose significant public health and economic challenges. This review aims to investigate the pathophysiological link between obesity and diabetes and evaluate emerging therapeutic strategies that involve glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, including their dual and triple agonist developments. A comprehensive literature review was conducted focusing on the mechanisms of glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, their clinical efficacy, and the evolution of combination therapies. Emphasis was placed on recent clinical trials and the development of oral agonist formulations to improve patient compliance. Glucagon-like peptide-1 receptor agonists, such as semaglutide and liraglutide, promote insulin secretion, suppress appetite, and result in effective weight loss and glycemic control. Semaglutide is available in both injectable and oral forms, improving accessibility. Liraglutide also reduces cardiovascular risk. Melanocortin-4 receptor agonists act via the central nervous system to reduce appetite and increase energy expenditure, with setmelanotide showing efficacy in genetic obesity. Dual and triple agonists, such as tirzepatide, simultaneously target glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, leading to enhanced metabolic outcomes. Oral drugs like rybelsus improve long-term adherence. Glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, particularly when used as dual or triple agents, represent promising therapeutic innovations for obesity and type 2 diabetes. The development of oral formulations further enhances treatment convenience and adherence, paving the way for improved clinical outcomes.
-
4. Is Hashimoto's Thyroiditis Associated with Insulin Resistance Markers?
PMID:期刊:日期:2026-09-01Hashimoto's thyroiditis causes cell death, hypothyroidism, and insulin resistance. Cholecystokinin, orexin-A, and cocaine and amphetamine-regulated transcript are essential regulators of various endocrine and autonomic processes, including food intake. We aimed to determine the cocaine and amphetamine-regulated transcript, orexin-A, and cholecystokinin levels in Hashimoto's thyroiditis patients and assess the relationships between the metabolic parameters and Hashimoto's thyroiditis. The present study was carried out in 45 Hashimoto's thyroiditis patients and 40 healthy control groups. Serum cocaine and amphetamine-regulated transcript levels (<0.05), homeostatic model assessment for insulin resistance (<0.05) and body mass index (<0.05) were significantly higher in Hashimoto's thyroiditis patients compared to the controls. Serum orexin-A levels were lower in Hashimoto's thyroiditis patients than those in the controls (<0.05). Serum cholecystokinin levels were similar between the two groups. A negative correlation was observed between orexin-A levels and cocaine and amphetamine-regulated transcript and cholecystokinin levels (=-0.365, <0.05; =- 0.297, <0.05, respectively). A positive correlation was observed between cocaine and amphetamine-regulated transcript levels and body mass index, insulin, and homeostatic model assessment for insulin resistance levels (=0.448, <0.01; =0.489, <0.01; =0.492, <0.01, respectively). Increased cocaine and amphetamine-regulated transcript and decreased orexin-A levels may be involved in the pathogenesis of Hashimoto's thyroiditis by controlling the thyroid-dependent immune system, insulin resistance, appetite, and body weight. We believe that our findings will lead to new developments in the diagnosis and treatment of this disease.
-
5. Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis.
PMID:期刊:日期:2026-09-01This meta-analysis aimed to clarify the association between glucagon-like peptide-1 receptor agonists, used for weight management in obesity, and the risks of pancreatitis and pancreatic cancer. We systematically searched PubMed, Web of Science, Embase, the Cochrane Library, and Scopus through June 15, 2026, for clinical studies conducted in obese populations. Peto odds ratios with 95% confidence intervals were calculated. Heterogeneity was assessed using ² statistic, and random-effects models were applied when ² exceeded 60%. Subgroup analyses were conducted according to study design, follow-up duration, control type, glucagon-like peptide-1 receptor agonist agent type, and dose regimen. Leave-one-out sensitivity analyses were additionally performed. This meta-analysis included 52 studies. The pooled analysis demonstrated no significant association between glucagon-like peptide-1 receptor agonist use and pancreatic cancer (odds ratio=1.34; 95% confidence interval: 0.76-2.34; =0.31) or pancreatitis (odds ratio=1.29; 95% confidence interval: 0.91-1.84; >0.05). Additional subgroup analyses according to study design, follow-up duration, control type, and dose regimen yielded findings consistent with the primary analyses. Leave-one-out sensitivity analyses were performed to assess the robustness of the pooled estimates. Glucagon-like peptide-1 receptor agonists used for weight management in obesity were not associated with an increased risk of pancreatitis or pancreatic cancer. The consistency of findings across multiple subgroup and sensitivity analyses further supports the pancreatic safety profile of glucagon-like peptide-1 receptor agonists.
-
6. The Relationship Between TPOAb and Osteoporosis: Moderating Effect of Visceral-to-Subcutaneous Fat Area Ratio.
PMID:期刊:日期:2026-09-01This cross-sectional study aimed to explore the relationship between thyroid peroxidase antibody (TPOAb) and osteoporosis, and the moderating effect of visceral-to-subcutaneous fat area ratio (VSR). A total of 128 males aged over 60 years with normal thyroid function and positive TPOAb (>9 IU/ml) were included. Lumbar spine, femoral neck, and whole-body bone mineral density (BMD) were measured by dual-energy X-ray absorptiometry. Visceral fat area (VFA) and subcutaneous fat area (SFA) were measured by the Omron DUALSCAN device. The relationships between TPOAb, VSR, interaction term (VSR*TPOAb) and BMD were analyzed using multiple linear regression models. Further subgroup analyses were performed stratified by VSR tertiles. TPOAb showed a significant negative correlation with BMD in the unadjusted model (p<0.01). However, when adjusted for confounding covariates, the correlation between TPOAb and BMD was no longer statistically significant (p>0.05). Further analysis showed VSR and the interaction term (VSR*TPOAb) were significantly negative associated with BMD in fully adjusted model (p<0.01). Subgroup analysis, stratified by VSR tertiles, showed that TPOAb only in T3 group (VSR>0.67) was negatively associated with lumbar spine and whole-body BMD (p<0.05). Hence, the relationship between TPOAb and BMD in elderly males varies with VSR. The abnormal body fat distribution may be a key moderator of the TPOAb-BMD relationship, suggesting the necessity for personalized bone health monitoring. Specifically, for patients with VSR>0.67, TPOAb screening is of great significance for the early prevention of osteoporosis.
-
7. Real-World Effectiveness and Safety of Recombinant Human Growth Hormone in Chinese Children with Noonan Syndrome: Long-Term Follow-Up and a 2-Year Comparison of Short- and Long-Acting Formulations.
PMID:期刊:日期:2026-09-01This retrospective real-world cohort study evaluated the effectiveness and safety of recombinant human growth hormone therapy in Chinese children with Noonan syndrome, with a predefined comparison between short-acting growth hormone and long-acting growth hormone during the first 2 years of treatment. Twenty children with Noonan syndrome were included; 16 were boys, and the median age at recombinant human growth hormone initiation was 5.55 years. The baseline height standard deviation score was-3.01. During the first 2 years, 10 patients received short-acting growth hormone and 10 patients received long-acting growth hormone. The median height standard deviation score increased to-2.20 after 1 year and-1.84 after 2 years, with significant longitudinal improvement over time. The cumulative change in height standard deviation score did not differ significantly between short-acting growth hormone and long-acting growth hormone at year 1 (0.58 vs. 0.71) or year 2 (1.01 vs. 1.30). First-year growth velocity was comparable between groups, whereas the apparent second-year difference was no longer significant after excluding short-acting growth hormone-treated patients who entered puberty and received adjunctive therapy. Among 16 patients with PTPN11 variants, the median cumulative change in height standard deviation score was 1.20 and 56.3% achieved an HtSDS of above-2 standard deviation score at the last follow-up. No diabetes mellitus, malignancy, new cardiovascular events, intracranial hypertension, or slipped capital femoral epiphysis occurred. Insulin-like growth factor-1 standard deviation score elevations were transient. Recombinant human growth hormone therapy was associated with sustained linear growth in children with Noonan syndrome, and short-acting growth hormone and long-acting growth hormone showed broadly comparable short-term efficacy under regular safety monitoring.
-
8. Early hormonal responses of irisin and nesfatin-1 following sleeve gastrectomy in women with obesity: A preliminary study.
PMID:期刊:日期:2026-08-28Laparoscopic sleeve gastrectomy (LSG) is an effective surgical intervention for morbid obesity, yet early hormonal changes contributing to metabolic adaptation remain underexplored. The objective of this study was to evaluate the early postoperative changes in the energy-regulating hormones irisin and nesfatin-1 following LSG in obese female patients. These hormones were selected due to their established roles in metabolic regulation and appetite control. This preliminary study included 27 women with obesity (body mass index, BMI>40 kg/m² or>35 kg/m² with comorbidities) undergoing LSG. Serum irisin and nesfatin-1 levels, body composition, and standard metabolic parameters were assessed preoperatively and at 1 month postoperatively. ELISA assays were used for hormone quantification. Repeated measures ANOVA and Spearman's correlation analyses were applied. One month postoperatively, serum irisin levels showed a significant increase (<0.001), whereas nesfatin-1 levels demonstrated a significant decrease (<0.001). Interestingly, nesfatin-1 exhibited a significant positive correlation with fat mass in the preoperative period; however, this relationship shifted to a negative correlation following the surgery, suggesting a potential alteration in regulatory mechanisms post-intervention. Reductions in BMI, fat mass, and muscle mass and improvements in glycemic and lipid profiles were also observed. The findings of this study reveal significant early postoperative shifts in irisin and nesfatin-1 levels following LSG, underscoring the potential regulatory role of these hormones in the body's initial metabolic adaptation to surgical weight loss.
-
9. Efficacy of Low Insulin-Like Growth Factor-1 Levels and a Single Insulin Tolerance Test in Diagnosing Growth Hormone Deficiency.
PMID:期刊:日期:2026-08-14Pediatric growth hormone deficiency requires dynamic testing for accurate diagnosis because of the pulsatile secretion of growth hormone. The insulin tolerance test (ITT) is regarded as one of the most robust individual provocative tests for growth hormone deficiency, although the broader pediatric diagnostic standard requires a composite of auxological, clinical, and biochemical criteria together with an inadequate response to two independent stimulation tests, except in specific high-probability contexts; insulin-like growth factor-1 (IGF-1) alone has limited diagnostic accuracy. This study evaluated whether combining low IGF-1 levels with a single failed ITT could improve diagnostic efficiency for pediatric growth hormone deficiency. We conducted a retrospective cohort study of 214 children with short stature (aged 2-16 y) evaluated at King Chulalongkorn Memorial Hospital between August 2019 and January 2025. Growth hormone deficiency was confirmed in 63 patients using two growth hormone stimulation tests (peak growth hormone level: < 7 ng/mL). IGF-1 levels were expressed as standard deviation scores and analyzed at cutoff values of ≤ -1, -1.5, -2, and -2.5 in combination with failed ITT results. Diagnostic performance indices were calculated at each predefined cutoff/test combination, including sensitivity, specificity, positive predictive values, negative predictive values, area under the receiver operating characteristic curve, odds ratios, and accuracy. An IGF-1 standard deviation score of ≤ -2.5 combined with a single failed ITT showed a sensitivity of 38.6% and a specificity of 92.6%, with a positive predictive value and a negative predictive value of 73.9% and 73.5%, respectively (<0.001). Because the reference standard for the growth hormone deficiency required failure of two stimulation tests, one of which was the ITT, we assessed this circularity directly: among 100 patients with both the ITT and clonidine results, findings were discordant in 37 (exact McNemar =0.008), and IGF-1 standard deviation scores did not differ significantly across concordant and discordant subgroups (Kruskal-Wallis =0.407). An IGF-1 standard deviation score cutoff of ≤ -2.5 combined with a single failed ITT identifies a subgroup of children at higher probability of growth hormone deficiency who may be prioritized for confirmatory evaluation. Given the modest sensitivity and positive predictive values of this criterion and the circularity inherent in a reference standard that itself incorporates the ITT, these findings should be regarded as hypothesis-generating rather than as a basis for changing current diagnostic practice, which continues to require two independent stimulation tests except in specific high-probability contexts; prospective, multicenter validation is required.
-
10. Normolipidemic Dysglycemia in Type 2 Diabetes: Clinical and Biochemical Characteristics of a Cohort Free of Lipid-Lowering and Chronic Anti-Inflammatory Therapy.
PMID:期刊:日期:2026-08-01In type 2 diabetes, hyperglycaemia usually clusters with atherogenic dyslipidaemia and low-grade inflammation; yet, these axes may dissociate in some patients. We aimed to estimate the prevalence of a normolipidemic dysglycemia phenotype in adults with type 2 diabetes and characterise its clinical-biochemical profile within an analytical window free of lipid-lowering and chronic anti-inflammatory/immunomodulatory therapy. In this retrospective, cross-sectional study, we analysed records of 1,046 adults aged 25-60 years with type 2 diabetes from a tertiary care hospital between 2020 and 2024. Individuals with other diabetes types, acute inflammatory conditions, malignancy, advanced organ failure and non-euthyroid status were excluded. Normolipidemic dysglycemia was defined as glycated hemoglobin≥64 mmol/mol with low-density lipoprotein cholesterol<100 mg/dL, triglycerides<150 mg/dL, high-density lipoprotein cholesterol≥40 mg/dL in men or≥50 mg/dL in women, and high-sensitivity C-reactive protein<5 mg/l in the absence of lipid-lowering or chronic anti-inflammatory/immunomodulatory therapy. Comparative analyses were restricted to a hyperglycaemic subpopulation free of lipid-lowering and chronic anti-inflammatory/immunomodulatory therapy (glycated hemoglobin≥64 mmol/mol; =183), while glucose-lowering treatment status was recorded separately and evaluated as a potential confounder. Normolipidemic dysglycemia was identified in 47/1,046 individuals (prevalence: 4.49%; 95% confidence interval: 3.40-5.92) and 47/183 individuals (prevalence: 25.7%; 95% confidence interval: 19.9-32.5) within the analytical subpopulation. Compared with atherogenic dysglycemia, normolipidemic dysglycemia showed lower triglycerides, lower high-sensitivity C-reactive protein, higher high-density lipoprotein cholesterol, higher fasting plasma glucose and higher creatinine-based estimated glomerular filtration rates. In multivariable models, higher fasting plasma glucose, longer diabetes duration and higher creatinine-based estimated glomerular filtration rates remained associated with normolipidemic dysglycemia, whereas age, sex and body mass index were not independently associated with normolipidemic dysglycemia. These findings identify a clinically detectable subgroup in which marked hyperglycaemia coexists with relatively preserved lipid and inflammatory markers. The normolipidemic dysglycemia construct reflects metabolic heterogeneity rather than established prognostic distinction and requires prospective validation with cardiovascular and renal outcomes.